The comorbidity conundrum: A focus on the role of noncardiovascular chronic conditions in the heart failure patient

Current Cardiology Reports

Volumn 14, Issue 3, 2012, Pages 276-284

  Page II, Robert Lee ^a   Lindenfeld, Joann ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Anemia; Chronic conditions; Chronic obstructive pulmonary disease; Comorbidities; Depression; Diabetes; Heart failure; Obesity; Osteoarthritis; Osteoporosis; Renal dysfunction; Thyroid dysfunction

Indexed keywords

AMIODARONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ESCITALOPRAM; GLITAZONE DERIVATIVE; LOOP DIURETIC AGENT; MEMANTINE; METOPROLOL SUCCINATE; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; SERTRALINE; TRASTUZUMAB; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUTE KIDNEY FAILURE; AGING; ALZHEIMER DISEASE; ARTICLE; BREAST CANCER; CARDIOVASCULAR RISK; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; FRACTURE; GOUT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HEART FAILURE; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MEDICARE; MORTALITY; OSTEOLYSIS; OUTPATIENT CARE; PATHOPHYSIOLOGY; PRESCRIPTION; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; THYROID DISEASE;

CHRONIC DISEASE; COMORBIDITY; DEPRESSIVE DISORDER; HEALTH RESOURCES; HEART FAILURE; HUMANS; PREVALENCE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84861101901     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0259-9     Document Type: Article

References (84)

1. Johns Hopkins School of Public Health. Chronic Conditions: Making the Case for Ongoing Care 2010. Available at http://www.rwjf.org/files/research/ 50968chronic.care.chartbook.pdf. Accessed December 2011. This is an excellent resource from Johns Hopkins that addresses all comorbidity within the United States utilizing multiple large data sources.
2. Anderson G, Horvath J. The growing burden of chronic disease in America. Public Health Rep. 2004;119:263-70.
3. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162:2269-76.
4. Marengoni A, Rizzuto D, Wang HX, et al. Patterns of chronic multimorbidity in the elderly population. J Am Geriatr Soc. 2009;57:225-30.
5. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209.
6. Metra M, Zaca V, Parati G, et al. Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. J Cardiovasc Med (Hagerstown). 2011;12:76-84. Published on behalf of the Heart Failure Study Group of the Italian Society of Cardiology, this is the most comprehensive review of the epidemiological, pathophysiological, and clinical characteristics of comorbidities as they impact HF treatment..
7. Masoudi FA, Krumholz HM. Polypharmacy and comorbidity in heart failure. BMJ. 2003;327:513-4.
8. Brunner-La Rocca HP, Buser PT, Schindler R, et al. Management of elderly patients with congestive heart failure-design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J. 2006;151:949-55.
9. Lang CC, Mancini DM. Non-cardiac comorbidities in chronic heart failure. Heart. 2007;93:665-71.
10. Ahluwalia SC, Gross CP, Chaudhry SI, et al. Change in comorbidity prevalence with advancing age among persons with heart failure. J Gen Intern Med. 2011;26:1145-51. Using Medicare beneficiaries, this is the first study to evaluate the impact of age on comorbidity burden..
11. Ahluwalia SC, Gross CP, Chaudhry SI, et al. Impact of comorbidity on mortality among older persons with advanced heart failure. J Gen Intern Med. 2011. Available at: http://www.springerlink.com/content/u838377v8wg07031/ fulltext.pdf Accessed December 2011. Using Medicare beneficiaries, these data provide the impact that comorbidities have on mortality in both hospitalized and nonhospitalizedpatients with HF
12. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226-33.
13. Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124:136-43. Using NHANES data, these data describe the increase in comorbidity and medication burden over the past two decades in patients with HF..
14. Druss BG, Marcus SC, Olfson M, et al. Comparing the national economic burden of five chronic conditions. Health Aff (Millwood). 2001;20:233-41.
15. Lee DS, Donovan L, Austin PC, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005;43:182-8.
16. Schneider KM, O'Donnell BE, Dean D. Prevalence of multiple chronic conditions in the United States' Medicare population. Health Qual Life Outcomes. 2009;7:82.
17. Page 2nd RL, Strongin K, Millis R, Hogan C, Lindenfeld J. Medicare beneficiaries with mild to severe heart failure See 15-23 different providers annually. Circulation. 2008;118:S-1030.
18. Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med. 2005;165:2069-76.
19. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drugdisease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447-50.
20. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516-20.
21. Page RL 2nd, Strongin K, Millis R, Hogan C, Lindenfeld J. The magnitude of health care resource utilization by Medicare beneficiaries with heart failure. Circulation. 2007;116:II-600.
22. Zhang JX, Rathouz PJ, Chin MH. Comorbidity and the concentration of healthcare expenditures in older patients with heart failure. J Am Geriatr Soc. 2003;51(4):476-82.
23. Oudejans I, Mosterd A, Zuithoff NP, Hoes AW. Comorbidity drives mortality in newly diagnosed heart failure: a study among geriatric outpatients. J Card Fail. 2012;18:47-52.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
25. Clarke B, Howlett J, Sapp J, et al. The effect of comorbidity on the competing risk of sudden and nonsudden death in an ambulatory heart failure population. Can J Cardiol. 2011;27:254-61.
26. Chaudhry SI, Wang Y, Gill TM, Krumholz HM. Geriatric conditions and subsequent mortality in older patients with heart failure. J Am Coll Cardiol. 2010;55:309-16.
27. Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol. 2008;51:93-102.
28. Page 2nd RL, Gozansky WS, Ruscin JM. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy. 2003;23:945-54.
29. Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T. Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol. 2010;61:509-21. This review describes in detail the relationship between the similarities in HFpathophysiology and development of central nervous system disorders..
30. Dec. GW. Anemia in heart failure time to rethink its etiology and treatment? J Am Coll Cardiol. 2006;48:2490-2.
31. Dimopoulou I, Daganou M, Tsintzas OK, Tzelepis GE. Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med. 1998;92:1321-5.
32. Agostoni P, Cattadori G, Guazzi M, Palermo P, Bussotti M, Marenzi G Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure. Am Heart J. 2000;140:e24.
33. Jefferson AL. Cardiac output as a potential risk factor for abnormal brain aging. J Alzheimers Dis. 2010;20:813-21.
34. Qiu C, Winblad B, Marengoni A, et al. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med. 2006;166:1003-8.
35. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010;170:1358-64.
36. Jagasia D, McNulty PH. Diabetes mellitus and heart failure. Congest Heart Fail. 2003;9:133-9.
37. Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol. 2006;26:296-306.
38. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004;116:305-11.
39. Ukena C, Mahfoud F, Kindermann M, et al. The cardiopulmonary continuum systemic inflammation as 'common soil' of heart and lung disease. Int J Cardiol. 2010;145:172-6.
40. Gnanasekaran G Epidemiology of depression in heart failure. Heart Fail Clin. 2011;7:1-10.
41. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116:1725-35.
42. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-13.
43. Faulx MD, Francis GS. Adverse drug reactions in patients with cardiovascular disease. Curr Probl Cardiol. 2008;33:703-68.
44. Maxwell CB, Jenkins AT. Drug-induced heart failure. Am J Health Syst Pharm. 2011;68:1791-804.
45. Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387-95.
46. van Diepen S, Majumdar SR, Bakal JA, et al. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16, 294 patients. Circulation. 2008;118:1946-52.
47. Rich MW. Heart failure in the oldest patients: the impact of comorbid conditions. Am J Geriatr Cardiol. 2005;14:134-41.
48. Jugdutt BI. Aging and heart failure: changing demographics and implications for therapy in the elderly. Heart Fail Rev. 2010;15:401-5.
49. Mascarenhas J, Azevedo A, Bettencourt P. Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortality. Curr Opin Pulm Med. 2010;16:106-11.
50. Mascarenhas J, Lourenco P, Lopes R, et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J. 2008;155:521-5.
51. Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Heart failure and COPD: partners in crime? Respirology. 2010;15:895-901.
52. Curkendall SM, DeLuise C, Jones JK et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63-70.
53. Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130-9.
54. Staszewsky L, Wong M, Masson S, et al. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail. 2007;13:797-804.
55. De Blois J, Simard S, Atar D, Agewall S. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail. 2010;16:225-9.
56. Boudestein LC, Rutten FH, Cramer MJ, et al. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail. 2009;11:1182-8.
57. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007;49:171-80.
58. Abroug F, Ouanes-Besbes L. Detection of acute heart failure in chronic obstructive pulmonary disease patients: role of B-type natriuretic peptide. Curr Opin Crit Care. 2008;14:340-7.
59. Tung RH, Camargo Jr CA, Krauser D, et al. Amino-terminal probrain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann Emerg Med. 2006;48:66-74.
60. de Groote P, Isnard R, Clerson P, et al. Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme. Eur J Heart Fail. 2009;11:85-91.
61. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977-2016.
62. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1-e194.
63. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-442.
64. van der Woude HJ, Zaagsma J, Postma DS, et al. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest. 2005;127:818-24.
65. Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009;11:684-90. This is one of the more robust studies evaluating bisoprolol in patients with underlying COPD..
66. Hawkins NM, Petrie MC, Macdonald MR, et al. Heart failure and chronic obstructive pulmonary disease the quandary of β-blockers and β-agonists. J Am Coll Cardiol. 2011;57:2127-38. This systematic review of the literature and guidelines specifically address the use the ji blockers and ji agonists, providing specific recommendations for HFpatients..
67. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55:1780-7. This is the a randomized, open-label triple crossover trial that demonstrates switching between β#41#5-selective β blockers and the nonselective β-blocker carvedilol is well tolerated but results in demonstrable changes in airway function in patients with COPD and HF..
68. Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48:1527-37.
69. Abramson J, Berger A, Krumholz HM, Vaccarino V. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med. 2001;161:1725-30.
70. Jaarsma T, Johansson P, Agren S, Stromberg A. Quality of life and symptoms of depression in advanced heart failure patients and their partners. Curr Opin Support Palliat Care. 2011;4:233-7.
71. Johansson P, Nieuwenhuis M, Lesman-Leegte I, et al. Depression and the delay between symptom onset and hospitalization in heart failure patients. Eur J Heart Fail. 2011;13:214-9.
72. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849-56.
73. Murberg TA, Furze G Depressive symptoms and mortality in patients with congestive heart failure: a six-year follow-up study. Med Sci Monit. 2004;10:CR643-8.
74. O'Connor CM, Jiang W, Kuchibhatla M, et al. Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med. 2008;168:2232-7.
75. Sherwood A, Blumenthal JA, Trivedi R, et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med. 2007;167:367-73.
76. Wu JR, Moser DK, De Jong MJ, et al. Defining an evidence-based cutpoint for medication adherence in heart failure. Am Heart J. 2009;157:285-91.
77. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005;366:2005-11.
78. Freedland KE, Carney RM, Rich MW. Effect of depression on prognosis in heart failure. Heart Fail Clin. 2011;7:11-21.
79. Sherwood A, Blumenthal JA, Hinderliter AL, et al. Worsening depressive symptoms are associated with adverse clinical outcomes in patients with heart failure. J Am Coll Cardiol. 2011;57:418-23.
80. Tousoulis D, Antonopoulos AS, Antoniades C, et al. Role of depression in heart failure-choosing the right antidepressive treatment. Int J Cardiol. 2010;140:12-8.
81. O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56:692-9. This is the first large, randomized placebocontrolled trial evaluating the impact of sertraline on both depression scores and cardiovascular events in patients with depression and HF..
82. Jiang W, Krishnan R, Kuchibhatla M, et al. Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). Am J Cardiol. 2011;107:545-51. This is a subanalysis of the SADHART-CHF study showing that remission from depression may improve the cardiovascular outcomes in patients with HF.
83. Angermann CE, Gelbrich G, Stork S, et al. Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail. 2007;9:1212-22.
84. Edelmann F, Stahrenberg R, Gelbrich G, et al. Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol. 2011;100:755-64.